National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Niraparib (Zejula®). HTA ID: 21004

Niraparib (Zejula®) is indicated as  monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.

NCPE Assessment Process Ongoing
Rapid review commissioned 22/02/2021
Rapid review completed 26/03/2021
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of niraparib (Zejula®) compared with the current standard of care.